The Dow Chemical Company

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Amgen Fremont Inc.

Celldex Therapeutics Limited

Other

Pfizer Corporation

Curagen Corporation

Abgenix, Inc.

Peter S Mezes

Brian B Gourlie

Jeffrey Schlom

Mark W Rixon

Ruth A Richard

Kimberly S Johnson

Donald A Kaplan

Michael Jeffers

Kam Fai Tse

Ian Nevin Foltz

Eduardo Agustin Padlan

Joseph A Affholter

Gregory M Landes

Luca Rastelli

Francine Zhifen Chen

Syed V S Kashmiri

W H Kerr Anderson

John L Herrmann

Orit Foord

Xiao-Chi Jia

Michael Torgov

Charles H Miller

Henri Lichenstein

Meina Liang

Richard August Shimkets

Scott L Klakamp

David R Stone

Ferenc L Boldog

Catherine Burgess

Kimberly Spytek

John R MacDougall

William LaRochelle

Stacie Casman

Bryan Zerhusen

Mehdi Mesri

Binyam Bezabeh

Nicolas J Kotite

Liming Shu

W H Anderson

Gary Starling

Nikolia Khramtsov

Linda L Gorman

Denise M Lepley

William Grosse

Andrew Eisen

Shlomit Edinger

Daniel K Rieger

Ivan G Otterness

Corine Vernet

John P Alsobrook, Ii

Juan Davagnino

Edward Voss

Karen Ellerman

Haihong Zhong

Steven Spaderna

Vincent DiPippo

John Peyman

Feng Xiao

Constance Berghs

Andrei Chapoval

Cyrus Karkaria

Vincent A Pollack

Gulshan Ara

James T Downs

Scott Klakamp

Michael E Jeffers

Henri Lichensten

Kam Fei Tse

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof

The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Antibodies directed to GPNMB and uses thereof

Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.

Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Proteins and nucleic acids encoding same

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V and V sequences which mediate TAG-72 binding and (2) human C and C regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C and C antibody domains. The nucleotide and amino acid sequences of V &agr;TAG V , CC46 V , CC49V , CC83 V , and CC92 V , and CC49V , CC83 V , and CC92 V idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

Probing method for identifying antibodies specific for selected antigens

Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains

The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.

Dimer and multimer forms of single chain polypeptides

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V,and V,sequences which mediate TAG-72 binding and (2) human C,and C,regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C,and C,antibody domains. The nucleotide and amino acid sequences of V,&agr;TAG V,, CC46 V,, CC49,, CC83 V,, and CC92 V,, and CC49,, CC83 V,, and CC92 V,idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

Family of high affinity, modified antibodies for cancer treatment

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

This invention provides novel antibodies and engineered versions thereof and methodology for monitoring biological media for protein fragments, especially collagen fragments resulting from collagenase cleavage of type II collagen.

Assays for measurement of protein fragments in biological media

This invention concerns a subset of composite Hum4 V.sub.L, V.sub.H antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have variable regions with (1) V.sub.L segments derived from the human subgroup IV germline gene, and (2) a V.sub.H segment which is capable of combining with the V.sub.L to form a three dimensional structure having the ability to bind TAG-72. In vivo methods of treatment and diagnostic assay using these composite antibodies is also disclosed.

Composite antibodies of human subgroup IV light chain capable of binding

Growing community of inventors

Midland, MI, United States of America

Peter S Mezes